Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, speaks about three new targeted therapies for acute myeloid leukemia (AML). These agents are BCL-2 inhibitor venetoclax, and FLT3 inhibitors quizartinib and gilteritinib. Dr Daver gives an overview of the positive data emerging from clinical trials of these therapies, and provides insight into what the next steps might be for them. He suggests the development of first-line combination therapies using these agents, and emphasizes the importance of reaching unequivocally preferable response rates compared to the current standard of care.
Developments in targeted AML therapies: venetoclax, quizartinib & gilteritinib
